Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hiltonol (Poly-ICLC) in Solid Cancers
NCT02423863Phase 2Completed
- Sponsor
- Oncovir, Inc.
- Start
- Mar 2015
- Primary completion
- Aug 2020
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of poly iclc in melanoma, head and neck squamous cell carcinoma (HNSCC), sarcoma, non-melanoma skin cancer (NMSC), sponsored by Oncovir, Inc.. Started Mar 2015; status: completed.
02
Drugs
poly iclc
03
Conditions
melanomahead and neck squamous cell carcinoma (HNSCC)sarcomanon-melanoma skin cancer (NMSC)
Beyond the preview
Go deeper on NCT02423863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02423863.